PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS-- TARGETING THE PARP PATHWAY FOR THE PREVENTION OF BREAST CANCER

Source: USASpending · CONT_AWD_75N91022F00001_7529_75N91019D00021_7529 · As of 2026-04-28 · Last synced 2026-11-10

Dates reflect the source record. Options and extensions exist; an end date does not establish that a contract will be recompeted, renewed, or terminated.

source record id

CONT_AWD_75N91022F00001_7529_75N91019D00021_7529

generated unique award id

CONT_AWD_75N91022F00001_7529_75N91019D00021_7529

source

USASpending

award id piid

75N91022F00001

vendor name as awarded

THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER

vendor uei

S3GMKS8ELA16

agency name

Department of Health and Human Services

sub agency

National Institutes of Health

contract title or description

PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS-- TARGETING THE PARP PATHWAY FOR THE PREVENTION OF BREAST CANCER

naics code

541714

naics description

RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)

psc code

AN12

texas nigp code

Not published

value obligated

1121090

Total / ceiling as published (not obligated)

Not published

pop start date

2022-06-01T05:00:00.000Z

expiry date

2027-05-31T05:00:00.000Z

place of performance state

TX

recipient location state

TX

set aside type

Not published

source as of

2026-04-28T05:00:00.000Z

last synced

2026-11-10T06:00:00.000Z

published

true

Source expiry field

Period of performance current end date (USASpending)